Exagen is a patient focused, discovery-driven life science company that addresses the unmet need for the accurate diagnosis and monitors patients affected by autoimmune rheumatic diseases. The company also provides AVISE tests that are specifically designed to provide objective information to physicians and patients for more accurate, efficient diagnosis, and better disease management. Exagen was established in 2002 and is headquartered in Vista, California.
Surefire Medical, based in Westminster, Colorado, was founded in 2009 to develop a novel infusion system for the interventional radiology market. The Surefire's Infusion System is designed to precisely deliver embolic agents through the sophisticated expandable tip portion of its catheter. Because of this differentiated expandable tip, which collapses in forwarding flow to maintain blood flow and dynamically expands to the vessel wall in reverse flow to minimize reflux, Surefire's Infusion System is designed to substantially reduce damage to healthy tissue.
CareSync is the leading provider of software and services for chronic disease management, combining technology with 24/7 nursing services to facilitate care coordination among patients, family and caregivers and all providers. CareSync provides turnkey Chronic Care Management services and a software-only option, allowing practices of any size to easily meet the billing requirements for CPT code 99490. Additionally, CareSync’s certified technology makes it simple for providers to meet Meaningful Use 2 for Data Exchange, Messaging, and Timely Access. CareSync patients are at the center of their healthcare, with access to health information, actionable goals, and Comprehensive Care Plan tasks, and as a result, are experiencing more productive medical appointments and better health outcomes.
CareSync is the leading provider of software and services for chronic disease management, combining technology with 24/7 nursing services to facilitate care coordination among patients, family and caregivers and all providers. CareSync provides turnkey Chronic Care Management services and a software-only option, allowing practices of any size to easily meet the billing requirements for CPT code 99490. Additionally, CareSync’s certified technology makes it simple for providers to meet Meaningful Use 2 for Data Exchange, Messaging, and Timely Access. CareSync patients are at the center of their healthcare, with access to health information, actionable goals, and Comprehensive Care Plan tasks, and as a result, are experiencing more productive medical appointments and better health outcomes.
OrthoSensor is an early-stage medical device company focused on developing and integrating advanced sensor technology in the Orthopedic field. The company is building a portfolio of intelligent, accurate, low-cost, and easy to use products that will extend from the operating room into the lifecycle of the implanted orthopedic device. Its intelligent orthopedic devices utilize advanced proprietary sensor and communications technologies, coupled with the company’s innovative software products, to facilitate evidence-based decisions in orthopedic surgery – with the goal of improving patient outcomes and potentially reducing the cost of treating musculoskeletal disease.
It was founded in 2006 and is headquartered in Dania, Florida.
CareSync is the leading provider of software and services for chronic disease management, combining technology with 24/7 nursing services to facilitate care coordination among patients, family and caregivers and all providers. CareSync provides turnkey Chronic Care Management services and a software-only option, allowing practices of any size to easily meet the billing requirements for CPT code 99490. Additionally, CareSync’s certified technology makes it simple for providers to meet Meaningful Use 2 for Data Exchange, Messaging, and Timely Access. CareSync patients are at the center of their healthcare, with access to health information, actionable goals, and Comprehensive Care Plan tasks, and as a result, are experiencing more productive medical appointments and better health outcomes.
Exagen is a patient focused, discovery-driven life science company that addresses the unmet need for the accurate diagnosis and monitors patients affected by autoimmune rheumatic diseases. The company also provides AVISE tests that are specifically designed to provide objective information to physicians and patients for more accurate, efficient diagnosis, and better disease management. Exagen was established in 2002 and is headquartered in Vista, California.
Exagen is a patient focused, discovery-driven life science company that addresses the unmet need for the accurate diagnosis and monitors patients affected by autoimmune rheumatic diseases. The company also provides AVISE tests that are specifically designed to provide objective information to physicians and patients for more accurate, efficient diagnosis, and better disease management. Exagen was established in 2002 and is headquartered in Vista, California.
Exagen is a patient focused, discovery-driven life science company that addresses the unmet need for the accurate diagnosis and monitors patients affected by autoimmune rheumatic diseases. The company also provides AVISE tests that are specifically designed to provide objective information to physicians and patients for more accurate, efficient diagnosis, and better disease management. Exagen was established in 2002 and is headquartered in Vista, California.
ESTECH is a privately held medical device manufacturing and distribution company located in San Ramon, California. The company was founded by Arthur and Raymond Bertolero in 1996 with an emphasis on least invasive products for cardiac surgery. ESTECH has worldwide distribution and has consistently attracted goal oriented professionals who represent the brightest minds in the medical device industry. The in-depth professional experience and tireless dedication of the ESTECH Team has allowed the company to achieve rapid and sustained success in this highly competitive environment. ESTECH is proud of each employee from every department and thanks them for their contribution and support.
Exagen is a patient focused, discovery-driven life science company that addresses the unmet need for the accurate diagnosis and monitors patients affected by autoimmune rheumatic diseases. The company also provides AVISE tests that are specifically designed to provide objective information to physicians and patients for more accurate, efficient diagnosis, and better disease management. Exagen was established in 2002 and is headquartered in Vista, California.
Exagen is a patient focused, discovery-driven life science company that addresses the unmet need for the accurate diagnosis and monitors patients affected by autoimmune rheumatic diseases. The company also provides AVISE tests that are specifically designed to provide objective information to physicians and patients for more accurate, efficient diagnosis, and better disease management. Exagen was established in 2002 and is headquartered in Vista, California.
Exagen is a patient focused, discovery-driven life science company that addresses the unmet need for the accurate diagnosis and monitors patients affected by autoimmune rheumatic diseases. The company also provides AVISE tests that are specifically designed to provide objective information to physicians and patients for more accurate, efficient diagnosis, and better disease management. Exagen was established in 2002 and is headquartered in Vista, California.
Exagen is a patient focused, discovery-driven life science company that addresses the unmet need for the accurate diagnosis and monitors patients affected by autoimmune rheumatic diseases. The company also provides AVISE tests that are specifically designed to provide objective information to physicians and patients for more accurate, efficient diagnosis, and better disease management. Exagen was established in 2002 and is headquartered in Vista, California.
ESTECH is a privately held medical device manufacturing and distribution company located in San Ramon, California. The company was founded by Arthur and Raymond Bertolero in 1996 with an emphasis on least invasive products for cardiac surgery. ESTECH has worldwide distribution and has consistently attracted goal oriented professionals who represent the brightest minds in the medical device industry. The in-depth professional experience and tireless dedication of the ESTECH Team has allowed the company to achieve rapid and sustained success in this highly competitive environment. ESTECH is proud of each employee from every department and thanks them for their contribution and support.
BioBehavioral Diagnostics Company manufactures and markets the Quotientâ„¢ ADHD System, a tool that aids in the objective and accurate assessment of ADHD symptoms. They are dedicated to providing physicians, parents and patients with high-value information to guide personalized strategies and to enhance quality of life for patients with ADHD.
Synageva is a biopharmaceutical company dedicated to developing and commercializing novel, next generation and follow on protein therapeutics that leverage the unique competitive advantages of their proprietary Synageva Expression Platform (SEPTM).
Coherex Medical, Inc. develops medical devices for addressing the structural heart disease conditions. It offers patent foramen ovale (PFO) closure system, which is designed to stimulate tissue in-growth to ensure long-term closure of the PFO.
The company was founded as Proximare, Inc. in 2003 and changed its name to Coherex Medical, Inc. in 2006. The company is based in Salt Lake City, Utah.
Vidacare Corporation, a medical device company, engages in the development, manufacture, and marketing of intraosseous access devices for diagnostic, monitoring, and therapeutic applications. The company provides EZ-IO Product System, which is designed to provide controlled vascular access through the intraosseous route to patients in emergent situations when vascular access is challenging and impossible. It also offers EZ-IO power driver, which is designed to penetrate the intraosseous space by drilling through the bone with a hollow needle and integrated stylet that doubles as the forward cutting bit to secure its correct placement; and EZ-IO Vascular Access Pack, a kit developed for emergency medical specialists to provide access to IV and IO devices to gain vascular access. In addition, the company provides a suite of hematology/oncology products, including a power driver and needle sets for bone marrow aspiration and biopsy; and OnControl, a bone marrow system for clinicians to perform bone marrow aspiration and biopsy procedures. Its products are used in pre-hospital, emergency, crash cart, and rapid response applications, as well as in military and homeland security industries. Vidacare Corporation was founded in 2001 and is headquartered in San Antonio, Texas.
Synageva is a biopharmaceutical company dedicated to developing and commercializing novel, next generation and follow on protein therapeutics that leverage the unique competitive advantages of their proprietary Synageva Expression Platform (SEPTM).
Atritech is a private company located in Minneapolis, Minnesota. The company was founded in 2000 and has developed proprietary technology focused on replacing long term anticoagulation therapy for patients with non-valvular atrial fibrillation at risk of stroke. The first implants of the WATCHMAN® Left Atrial Appendage Closure Technology were performed in Germany in August of 2002 and in the United States in October of 2003. Since then the company has conducted a large randomized clinical trial comparing the WATCHMAN® Left Atrial Appendage Closure Technology to long term Warfarin therapy in patients with non-valvular atrial fibrillation at risk of stroke. The WATCHMAN® Device is CE Marked and available in many markets outside the United States. The WATCHMAN® Device is currently available For Investigational Use Only in the United States.
ALDAGEN is a biopharmaceutical company developing proprietary regenerative cell therapies that target significant unmet medical needs. We have four product candidates in clinical trials. Our most advanced product candidate is ALD-101. We are currently conducting a pivotal Phase 3 clinical trial of ALD-101 to evaluate its efficacy in improving umbilical cord blood, or cord blood, transplants used to treat inherited metabolic diseases in pediatric patients. We are also conducting or supporting Phase 1 or Phase 1/2 clinical trials of three other product candidates ALD--151 to improve cord blood transplants used for the treatment of leukemia; ALD-301 to treat critical limb ischemia; and ALD-201 to treat ischemic heart failure.
Atritech is a private company located in Minneapolis, Minnesota. The company was founded in 2000 and has developed proprietary technology focused on replacing long term anticoagulation therapy for patients with non-valvular atrial fibrillation at risk of stroke. The first implants of the WATCHMAN® Left Atrial Appendage Closure Technology were performed in Germany in August of 2002 and in the United States in October of 2003. Since then the company has conducted a large randomized clinical trial comparing the WATCHMAN® Left Atrial Appendage Closure Technology to long term Warfarin therapy in patients with non-valvular atrial fibrillation at risk of stroke. The WATCHMAN® Device is CE Marked and available in many markets outside the United States. The WATCHMAN® Device is currently available For Investigational Use Only in the United States.
ALDAGEN is a biopharmaceutical company developing proprietary regenerative cell therapies that target significant unmet medical needs. We have four product candidates in clinical trials. Our most advanced product candidate is ALD-101. We are currently conducting a pivotal Phase 3 clinical trial of ALD-101 to evaluate its efficacy in improving umbilical cord blood, or cord blood, transplants used to treat inherited metabolic diseases in pediatric patients. We are also conducting or supporting Phase 1 or Phase 1/2 clinical trials of three other product candidates ALD--151 to improve cord blood transplants used for the treatment of leukemia; ALD-301 to treat critical limb ischemia; and ALD-201 to treat ischemic heart failure.
Impulse Monitoring provides a range of intra-operative neurophysiologic monitoring solutions to hospitals and other healthcare facilities. It offers insight into the nervous system during spinal, nerve, and brain-related surgeries. Through the use of its product, IONM, surgeons can reduce surgical risk by providing critical information and alerts on potential harm or compromise to the spinal cord or neural structures. IONM provides better insight into a patient’s condition during surgery to support better decision-making that enables the practice of better medicine. Impulse Monitoring is based in Columbia, Maryland.
BioBehavioral Diagnostics Company manufactures and markets the Quotientâ„¢ ADHD System, a tool that aids in the objective and accurate assessment of ADHD symptoms. They are dedicated to providing physicians, parents and patients with high-value information to guide personalized strategies and to enhance quality of life for patients with ADHD.
Adiana, Inc. engages in the development and testing of transcervical sterilization system for permanent birth control. It develops Complete TCS, which consists of a radiofrequency generator, delivery catheter, and implantable matrix. The company was founded in 1997 and is based in Redwood City, California. As of March 16, 2007, Adiana, Inc. is a subsidiary of CYTYC Corp.
Exagen is a patient focused, discovery-driven life science company that addresses the unmet need for the accurate diagnosis and monitors patients affected by autoimmune rheumatic diseases. The company also provides AVISE tests that are specifically designed to provide objective information to physicians and patients for more accurate, efficient diagnosis, and better disease management. Exagen was established in 2002 and is headquartered in Vista, California.
myocor is a medical company that develops and distributes a range of therapeutic products to its clients. The company develops and provides evaluations on technologies to treat mitral regurgitation and heart failure. Furthermore, the technologies assist in the improvement of cardiac function. myocor was founded in 1996 and is based in Minnesota.
Valeo Medical
Series B in 2004
Valeo Medical, Inc., a life sciences company, develops a non-invasive diagnostic blood test for endometriosis. The company was founded in 2003 and is based in Burlington, Massachusetts. Valeo raised money as part of the Discovery Life Sciences fund which was partly funded by the Nashville Capital Network.
BioRexis has developed proprietary protein engineering technologies based upon human transferrin that provide novel therapeutic agents with longer duration of action than synthetic peptides. In addition to reducing dosing frequency, these technologies have the potential to substantially improve patient tolerability. This new platform supports Pfizer’s commitment to develop novel protein therapeutic agents.
TransMolecular, Inc. is a neuroscience biotechnology company committed to discovering, developing and commercializing novel and proprietary drugs to diagnose and treat diseases of the central nervous system having inadequate pharmaceutical alternatives. The Company focuses its drug development on cancer and pain, and has built strong technology platforms to enrich its product discovery and development pipeline. Founded in July 1996, TransMolecular is privately held and venture capital backed, having raised $9.6MM to date through two private placements from internationally recognized investment firms. The Company has built a strong management team that is dedicated to the discovery and development of safe and effective products for patients suffering from cancer and pain. Its management team has more than 75 years of combined relevant experience in healthcare, pharmaceutical development, R&D, operations, and finance. TransMolecular's corporate offices and R&D laboratories are in Birmingham, Alabama. TransMolecular has received three Small Business Incentive Research (SBIR) grants totaling $1 million from the National Institutes of Health for its cancer and pain programs. The Company holds more than 25 patents and/or patent applications to protect its products worldwide, and has exclusive license agreements with the University of Alabama at Birmingham Research Foundation and Yale University for its cancer and pain technology, respectively.
Exagen is a patient focused, discovery-driven life science company that addresses the unmet need for the accurate diagnosis and monitors patients affected by autoimmune rheumatic diseases. The company also provides AVISE tests that are specifically designed to provide objective information to physicians and patients for more accurate, efficient diagnosis, and better disease management. Exagen was established in 2002 and is headquartered in Vista, California.
Valeo Medical
Series A in 2003
Valeo Medical, Inc., a life sciences company, develops a non-invasive diagnostic blood test for endometriosis. The company was founded in 2003 and is based in Burlington, Massachusetts. Valeo raised money as part of the Discovery Life Sciences fund which was partly funded by the Nashville Capital Network.
BioRexis has developed proprietary protein engineering technologies based upon human transferrin that provide novel therapeutic agents with longer duration of action than synthetic peptides. In addition to reducing dosing frequency, these technologies have the potential to substantially improve patient tolerability. This new platform supports Pfizer’s commitment to develop novel protein therapeutic agents.
TransMolecular, Inc. is a neuroscience biotechnology company committed to discovering, developing and commercializing novel and proprietary drugs to diagnose and treat diseases of the central nervous system having inadequate pharmaceutical alternatives. The Company focuses its drug development on cancer and pain, and has built strong technology platforms to enrich its product discovery and development pipeline. Founded in July 1996, TransMolecular is privately held and venture capital backed, having raised $9.6MM to date through two private placements from internationally recognized investment firms. The Company has built a strong management team that is dedicated to the discovery and development of safe and effective products for patients suffering from cancer and pain. Its management team has more than 75 years of combined relevant experience in healthcare, pharmaceutical development, R&D, operations, and finance. TransMolecular's corporate offices and R&D laboratories are in Birmingham, Alabama. TransMolecular has received three Small Business Incentive Research (SBIR) grants totaling $1 million from the National Institutes of Health for its cancer and pain programs. The Company holds more than 25 patents and/or patent applications to protect its products worldwide, and has exclusive license agreements with the University of Alabama at Birmingham Research Foundation and Yale University for its cancer and pain technology, respectively.
SupplyPro®'s inventory management systems for the Maintenance, Repair and Operations environment control inventory from point-of-use to replenishment. Our web-based "inventory management" units maintain an extremely cost-effective just-in-time inventory, eliminating critical stock-outs. When supplies reach a pre-determined "low", our systems automatically reorder from your supplier.
AmericasDoctor, a unique pharmaceutical services company, combines and integrates leading physician researchers, strategic marketing and consumer outreach capabilities, distinguished hospitals and advanced Internet resources to assist the pharmaceutical industry in developing, positioning and promoting its products. AmericasDoctor was formed in January 2000 from a merger between Affiliated Research Centers (ARC) and AmericasDoctor.com. AmericasDoctor Research Services (formerly ARC) provides investigative site and patient recruitment capabilities through its 150 investigative sites operating in 37 states in the U.S. and five provinces in Canada. Currently, AmericasDoctor is conducting over 550 studies in urology, rheumatology, pulmonology and respiratory disease, endocrinology, cardiology, women’s health, gastroenterology and neuroscience. AmericasDoctor Web Services provides information to consumers in response to health information inquiries. It is the only medical/health Internet site to offer private, real-time, one-on-one chats with board-certified, board-eligible physicians 24 hours a day, seven days a week at no cost to the consumer. This site is sponsored by over 100 leading U.S. hospitals. AmericasDoctor supports the combined efforts of the medical community and pharmaceutical industry to improve the lives of people suffering from chronic illnesses. AmericasDoctor provides the vital link between the patient, the medical expert and the development of new therapies. To the consumer, this means enhanced lives, the empowerment to manage their medical situations and the possibility of improved treatment efficacy. For pharmaceutical companies, this means unique approaches in defining, developing and expediting new products and solutions. AmericasDoctor is a privately held company with a strategic vision to provide a new generation of pharmaceutical services integrating information, marketing and research resources to help create tomorrow’s medicine.
Centromine
Venture Round in 1999
Centromine offers a browser-based, internet-accessed, enterprise-wide software applications and services for the health care market. Its applications allow behavioral health care programs and providers to manage the delivery and associated quality and cost of services completely over the internet.
TransMolecular, Inc. is a neuroscience biotechnology company committed to discovering, developing and commercializing novel and proprietary drugs to diagnose and treat diseases of the central nervous system having inadequate pharmaceutical alternatives. The Company focuses its drug development on cancer and pain, and has built strong technology platforms to enrich its product discovery and development pipeline. Founded in July 1996, TransMolecular is privately held and venture capital backed, having raised $9.6MM to date through two private placements from internationally recognized investment firms. The Company has built a strong management team that is dedicated to the discovery and development of safe and effective products for patients suffering from cancer and pain. Its management team has more than 75 years of combined relevant experience in healthcare, pharmaceutical development, R&D, operations, and finance. TransMolecular's corporate offices and R&D laboratories are in Birmingham, Alabama. TransMolecular has received three Small Business Incentive Research (SBIR) grants totaling $1 million from the National Institutes of Health for its cancer and pain programs. The Company holds more than 25 patents and/or patent applications to protect its products worldwide, and has exclusive license agreements with the University of Alabama at Birmingham Research Foundation and Yale University for its cancer and pain technology, respectively.